Cargando…
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons
Background. The determination of the safety profile of any vaccine is critical to its widespread use in any population. In addition, the application of international guidelines to fit local context could be a challenging but important step toward obtaining quality safety data. Methods. In clinical s...
Autores principales: | Enwere, Godwin C., Paranjape, Gandhali, Kulkarni, Prasad S., Ginde, Manisha, Hartmann, Katharina, Viviani, Simonetta, Chaumont, Julie, Martellet, Lionel, Makadi, Marie-Francoise, Ivinson, Karen, Marchetti, Elisa, Herve, Jacques, Kertson, Kim, LaForce, F. Marc, Preziosi, Marie-Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639488/ https://www.ncbi.nlm.nih.gov/pubmed/26553681 http://dx.doi.org/10.1093/cid/civ509 |
Ejemplares similares
-
Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine
por: Martellet, Lionel, et al.
Publicado: (2015) -
Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa
por: Okwo-Bele, Jean-Marie, et al.
Publicado: (2015) -
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
por: Tapia, Milagritos D., et al.
Publicado: (2015) -
Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
por: Tapia, Milagritos D., et al.
Publicado: (2015) -
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
por: Diallo, Aldiouma, et al.
Publicado: (2015)